Regeneron Pharmaceuticals Inc

Regeneron (REGN) reported its Q2 earnings results before the markets opened. REGN reported revenues of $1.93 billion, a YoY increase of 20%.

In the first quarter, Sanofi’s (SNY) Immunology Franchise reported net sales of 359 million euros.

In the first quarter, Sanofi’s (SNY) Oncology franchise reported net sales of 399 million euros, a YoY rise of 7.8% on a CER (constant exchange rate) basis.

Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.

On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.

Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

In the third quarter, Austedo reported revenues of $62 million, which is a YoY rise of 933.33% and a sequential rise of 40.91%.

On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.

Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.

Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

Alnylam Pharmaceuticals (ALNY) is currently trading 1.47% higher than its 52-week low price of $78.85 and 48.04% lower than its 52-week high price of $153.99.

On October 15, Regeneron (REGN) closed at $377.55, which was 1.72% lower than its previous closing price on October 12.

Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

In 4Q17, Amgen’s (AMGN) Repatha generated revenues of $98 million, which reflected a 69% growth YoY (year-over-year) and a 10% growth quarter-over-quarter.

Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.

On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.

Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.

Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.

Teva Pharmaceutical Industries (TEVA) has risen ~9% over the last five days.

Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr.

Wall Street analysts have projected Vertex Pharmaceuticals’ fiscal 2018 adjusted diluted EPS to be around $3.8, which would be a YoY rise of approximately 93.1%.

In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million.

In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes.

In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.

Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.

Today, Tonix Pharmaceuticals (TNXP) was trading at $4.23, which represents ~7.09% growth from yesterday’s close of $3.95.

Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

On July 3, Exelixis (EXEL) stock closed at $21.4, a ~15.7% increase from its 52-week low of $18.5 on May 10.

A label expansion could further advance Dupixent’s position in the atopic dermatitis market.

On March 19, Regeneron announced positive top line results from its Phase 3 PANORAMA trial.

Regeneron (REGN) currently has six FDA-approved drugs and 17 investigational therapies in its research pipeline.

On June 19, 2018, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, the stock price hit a 52-week high of $54.84.

Jobs data released this morning shows that the U.S. economy is firing on all cylinders, and the stock market has responded by rallying.

Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.

Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21.

MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.

In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17.

In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17.

In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.

In April 2018, AbbVie (ABBV) positive results for its Phase 3 SELECT-COMPARE trial, which evaluated the safety and efficacy of upadacitinib for adults with moderate-to-severe rheumatoid arthritis.

In April 2017, the FDA approved a supplemental biologics license application (or sBLA) for Praluent for a once-monthly dose.

On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53.

In 4Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $139.0 million compared to $88.9 million in 3Q17.

In 4Q17, Eylea generated net global revenues of $1.6 billion compared to ~$1.4 billion in 4Q16.

Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”

In 4Q17, Novartis’s Ophthalmology business generated revenues of $1.35 billion, which reflected ~2% growth on a year-over-year (or YoY) basis and ~2% growth quarter-over-quarter.

Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is a drug designed for the treatment of spinal muscular atrophy.

Ionis (IONS) is a leading biopharmaceutical company focused on discovering, developing, and commercializing RNA-targeted therapies.

Novartis (NVS) plans to submit to an FDA application seeking regulatory approval for investigational drug RTH258.

Regeneron Pharmaceuticals (REGN) generated total revenues of $5.8 billion in fiscal 2017 compared with $4.8 billion in fiscal 2016.

Regeneron Pharmaceuticals (REGN) currently has 15 products in clinical development.

In January 2017, Regeneron Pharmaceuticals’ (REGN) Kevzara was approved in Canada for the treatment of patients with active rheumatoid arthritis.

Globally, Regeneron Pharmaceuticals’ (REGN) Eyelea generated $5.9 billion in sales in fiscal 2017 compared with $5.1 billion in fiscal 2016.

In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.

In 1Q17, 2Q17, and 3Q17, Repatha generated revenues of $49.0 million, $83.0 million, and $89.0 million, respectively.

On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.

Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

Eucrisa growth trends On December 14, 2016, Pfizer (PFE) announced that it had secured FDA approval for its mild-to-moderate AD (atopic dermatitis) therapy, Eucrisa (crisaborole) 2% ointment, for patients over two years old. This drug was added to Pfizer’s portfolio through the acquisition of Anacor Pharmaceuticals, which was completed in June 2016 for ~$5.2 billion. […]

In May 2017, the US FDA (Food and Drug Administration) approved Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) Kevzara (sarilumab) for the treatment individuals with moderate to severe rheumatoid arthritis.

In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

Dupilumab could be long-term growth driver In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety and efficacy of dupilumab for the treatment of individuals with severe steroid-dependent asthma. In the study, at 24 weeks, when […]

In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

In 3Q17, Roche Holding’s (RHHBY) Lucentis generated revenues of 399 million Swiss francs, which reflected ~7% growth on a year-over-year (or YoY) basis.

After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion.

Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”

According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.

In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.

Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.

Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).

In September 2017, Amgen presented new analysis from the cardiovascular outcomes study.

In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

In 1H17, Novartis’s (NVS) Travoprost drugs reported revenues of around $290 million, which is a ~6% decline on a YoY basis.

In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

In 2Q17, Mylan reported revenues close to $3.0 billion, which is a YoY rise of around 16.0%, mainly driven by increased sales in Europe and the Rest of World markets.

The iShares NASDAQ Biotechnology ETF (IBB) aims to track the investment results of the NASDAQ Biotechnology Index, which comprises NASDAQ-listed biotechnology and pharmaceuticals companies.

Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.

Dupixent combined with standard of care also showed 12%–15% improvement in FEV1 from baseline in asthma patients after 12 weeks of treatment compared to those treated with standard of care alone.

In June 2017 and July 2017, healthcare providers wrote prescriptions for Regeneron (REGN) and Sanofi’s (SNY) Dupixent for 750 new patients on a weekly basis.

In 1H17, Eylea’s total sales rose 10% on a year-over-year basis.

Regeneron is currently studying the drug in combination with nesvacumab, an antibody to angiopoietin 2, in two Phase 2 trials, in wet AMD and diabetic macular edema indications.

Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”

In 2Q17, Regeneron Pharmaceuticals’ (REGN) Dupixent generated revenues of $28.6 million.

Twenty-five analysts were analyzing Regeneron Pharmaceuticals in August 2017. Seven of them recommended a “strong buy,” and five recommended a “buy.”

Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”